S-1: Profusa Files for Resale of Over 179 Million Shares

Profusa, Inc. has filed a registration statement with the SEC to permit the resale of up to 179,272,293 shares of its common stock by selling stockholders.

Summary

• Profusa, Inc. has filed a registration statement with the SEC to allow for the resale of up to 179,272,293 shares of its common stock by selling stockholders.
• These shares are held by Ascent Partners Fund LLC and NorthView Sponsor I, LLC.
• The shares being registered include those purchased under an Equity Line of Credit (ELOC) Purchase Agreement, shares issuable upon conversion of convertible notes, and shares issuable upon exercise of warrants.
• The company will not receive proceeds from these resales, but may receive up to $100 million from future sales to Ascent under the ELOC Purchase Agreement.
• The filing also details the company's business, financial condition, risk factors, and management.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant financial challenges, Nasdaq delisting concerns, and substantial dilution risks, despite the company's technological potential.

Positives

• The company has secured a committed equity facility of up to $100 million from Ascent Partners Fund LLC, providing potential future capital.
• Profusa has received CE approval for its Lumee Oxygen Platform in the EU and is working towards FDA approval in the U.S.
• The company has a strong intellectual property portfolio with 25 issued U.S. patents and 32 rest-of-world patents.
• Profusa has a license agreement with Mayo Foundation for Medical Education and Research, expanding its technological capabilities.
• The company's Lumee Glucose platform has shown promising proof-of-concept clinical data with a mean absolute relative difference (MARD) of approximately 11% and up to nine months of functionality.

Negatives

• The company has a history of net losses and expects to continue incurring significant losses for the foreseeable future.
• Profusa has substantial doubt about its ability to continue as a going concern.
• The company has received notices from Nasdaq regarding non-compliance with continued listing requirements, including minimum bid price and market value of listed securities, and is subject to potential delisting.
• The potential issuance of a material number of additional shares of common stock could result in significant dilution to existing stockholders and depress the market price.
• The company has a limited operating history and has not yet achieved profitability.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to recurring losses and the need for additional financing.
• Failure to regain compliance with Nasdaq continued listing requirements could lead to delisting, impacting liquidity and investor confidence.
• The sale and issuance of common stock under the ELOC Purchase Agreement will cause dilution to existing stockholders, and the perception of future sales could depress the stock price.
• If the company's common stock trades below the floor price under the ELOC Purchase Agreement, it will be unable to sell shares, materially limiting its access to capital.
• The company faces significant competition from large, well-established companies in the digital health and medical technology sectors.
• Obtaining FDA clearance or approval for its products is a lengthy and uncertain process, and failure to do so would adversely affect the company's ability to grow.
• The company has identified material weaknesses in its internal control over financial reporting, which could adversely affect its ability to report accurately and timely.
• The company has a limited operating history and has incurred losses since inception, with expectations of continued losses for several years.

Future Outlook

The company expects to continue incurring significant losses for at least the next several years as it commercializes its existing products and develops new ones. Its future success depends on obtaining regulatory approvals, market acceptance, and securing additional financing.

Management Comments

• Profusa believes that the combination of the potential advantages of its platform will enable it to generate both short-term revenue in high-value clinical applications and to leverage core technology for future product development.
• Profusa believes that its technological approach may create advantages to current glucose monitoring solutions on the market to substantially increase the number of users who can benefit from this data stream.
• Profusa believes that, at scale, the data its platform generates from its initial products will be a key enabler for the productivity and business models for telemedicine and health and wellness coaching sectors.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive digital health and medical technology sector, focusing on biosensing solutions. The company's Lumee Oxygen and Lumee Glucose platforms aim to address critical needs in wound care and diabetes management, respectively, by providing real-time biochemical data. The market for continuous glucose monitoring (CGM) is substantial, with significant players like Dexcom, Abbott, and Medtronic. Profusa's strategy involves leveraging its proprietary hydrogel sensor technology, which it claims offers longer functionality and easier deployment compared to existing solutions, and pursuing partnerships to expand its market reach, particularly in Europe and Asia.

Comparison to Industry Standards

• Profusa's Lumee Oxygen platform aims to provide tissue oxygen levels for up to six months, which is significantly longer than the typical 7-14 day lifespan of current CGM sensors that are susceptible to foreign body response.
• The Lumee Glucose platform, in clinical studies, has demonstrated a mean absolute relative difference (MARD) of approximately 11%, which is comparable to industry-leading CGM devices.
• Profusa's sensor deployment method, using a hypodermic needle injection, is presented as less invasive and potentially lower cost than surgical implantation required by some other long-term implantable CGM systems.
• The company's strategy to partner with telemedicine and health and wellness platforms aims to leverage existing user bases and infrastructure, a common approach in the digital health sector to scale adoption.

Corporate Governance

Legal Proceedings

• A vendor litigation resulted in a judgment in favor of the vendor, with the company accruing approximately $0.1 million as of December 31, 2025.
• A former employee has made a demand for unpaid wages of approximately $0.2 million, including statutory penalties, which has been accrued for.

Related Party Transactions

• Profusa has outstanding convertible notes and loans payable with related parties, including Tasly and NorthView Sponsor I, LLC.
• The company has a convertible working capital promissory note with the Sponsor (NorthView Sponsor I, LLC) for up to $2.5 million, with $1.9 million outstanding as of December 31, 2025.
• The company has an outstanding convertible note with Tasly, a shareholder, with $2.3 million outstanding as of December 31, 2025.

Stakeholder Impact

• Existing shareholders face potential dilution from future share issuances under the ELOC and warrant exercises.
• The risk of delisting from Nasdaq could negatively impact the market price of common stock and investor confidence.
• The company's ability to secure future financing is critical for its operations and growth, impacting all stakeholders.
• The company's focus on technological development and regulatory approvals is key to delivering value to shareholders and patients.

Next Steps

• Obtain FDA clearance or approval for Lumee Oxygen and Lumee Glucose products in the U.S.
• Initiate commercialization efforts for Lumee Oxygen in Europe in early 2026.
• Continue discussions with potential partners in Asia for joint ventures.
• Regain compliance with Nasdaq continued listing requirements.
• Execute on the ELOC Purchase Agreement to raise capital as needed.

Key Dates

Recommendation

While Profusa possesses innovative technology with potential in the biosensing market, the significant financial challenges, including substantial losses, doubt about going concern, and Nasdaq delisting risks, outweigh the near-term positive outlook. The potential for significant dilution from ongoing financing activities also presents a considerable risk. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of financial stability, regulatory approvals, and successful commercialization.

Keywords

Profusa, SEC Filing, Form S-1, Registration Statement, Common Stock, Resale, Selling Stockholders, Ascent Partners Fund LLC, NorthView Sponsor I, LLC, ELOC Purchase Agreement, Convertible Notes, Warrants, Digital Health, Biosensors, Lumee Oxygen, Lumee Glucose, Biotechnology, Medical Devices, Capital Raise